Hey, naysayers: Bristol-Myers' Celgene buy just chalked up another point in its favor

6th June 2019 Uncategorised 0

Bristol-Myers Squibb scored more bragging rights for its coming megamerger: The FDA is now officially reviewing one of the “Big 5” Celgene candidates touted as cornerstones of the deal. And it’s ozanimod, the blockbuster MS prospect whose application the FDA wouldn’t even consider last year.

More: Hey, naysayers: Bristol-Myers' Celgene buy just chalked up another point in its favor
Source: fierce